PURPOSE: To evaluate treatment outcomes and toxicity in patients with stage T1-3N0M0 oral cancer treated with surgery followed by high-dose-rate brachytherapy (HDR-BT). METHODS AND MATERIALS: Retrospective study of 50 patients with stage T1-T3N0 tongue and floor-of-mouth cancer who underwent tumour excision (+ elective neck dissection) followed by postoperative HDR-BT due to the presence of negative prognostic factors (close or positive resection margins, lymphovascular and/or perineural invasion, deep invasion). The plastic tube technique (dose: 18 x 3 Gy b.i.d.) was used. Survival outcomes, toxicity, and prognostic factors were evaluated. RESULTS: At a median follow-up of 81 months (range, 4-121), actuarial 5-year local control (LC), nodal control (NC) and progression-free survival (PFS) rates were 79%, 69%, and 64%. After salvage treatment (surgery + external beam radiotherapy), LC, NC, and PFS increased to 87%, 77%, and 72.3%, respectively. Five-year overall survival and cancer-specific survival (CSS) rates were 73% and 77%. Treatmentrelated toxicity included two cases of mandibular osteoradionecrosis and five cases of small soft tissue necrosis. T stage was significantly correlated with nodal control (p=0.02) and CSS (p=0.04). Tumour grade correlated with DFS (p=0.01). CONCLUSION: Postoperative HDR-BT 18 x 3 Gy b.i.d. seems to be an effective method in patients with T1-3N0M0 oral cancer with negative prognostic factors after tumour resection.

• MeSH
• Brachytherapy * methods   MeSH
• Radiotherapy Dosage * MeSH
• Adult MeSH
• Middle Aged MeSH
• Humans MeSH
• Survival Rate MeSH
• Mouth Neoplasms * radiotherapy   pathology   surgery   MeSH
• Prognosis MeSH
• Retrospective Studies MeSH
• Aged, 80 and over MeSH
• Aged MeSH
• Neoplasm Staging * MeSH
• Treatment Outcome MeSH
• Check Tag
• Adult MeSH
• Middle Aged MeSH
• Humans MeSH
• Male MeSH
• Aged, 80 and over MeSH
• Aged MeSH
• Female MeSH
• Publication type
• Journal Article MeSH

INTRODUCTION: The histopathological classification for antineutrophil cytoplasmic autoantibody (ANCA)-associated glomerulonephritis (ANCA-GN) is a well-established tool to reflect the variety of patterns and severity of lesions that can occur in kidney biopsies. It was demonstrated previously that deep learning (DL) approaches can aid in identifying histopathological classes of kidney diseases; for example, of diabetic kidney disease. These models can potentially be used as decision support tools for kidney pathologists. Although they reach high prediction accuracies, their "black box" structure makes them nontransparent. Explainable (X) artificial intelligence (AI) techniques can be used to make the AI model decisions accessible for human experts. We have developed a DL-based model, which detects and classifies the glomerular lesions according to the Berden classification. METHODS: Kidney biopsy slides of 80 patients with ANCA-GN from 3 European centers, who underwent a diagnostic kidney biopsy between 1991 and 2011, were included. We also investigated the explainability of our model using Gradient-weighted Class Activation Mapping (Grad-CAM) heatmaps. These maps were analyzed by pathologists to compare the decision-making criteria of humans and the DL model and assess the impact of different training settings. RESULTS: The DL model shows a prediction accuracy of 93% for classifying lesions. The heatmaps from our trained DL models showed that the most predictive areas in the image correlated well with the areas deemed to be important by the pathologist. CONCLUSION: We present the first DL-based computational pipeline for classifying ANCA-GN kidney biopsies as per the Berden classification. XAI techniques helped us to make the decision-making criteria of the DL accessible for renal pathologists, potentially improving clinical decision-making.

• Publication type
• Journal Article MeSH

BACKGROUND AND OBJECTIVE: While active surveillance (AS) is an alternative to surgical interventions in patients with small renal masses (SRMs), evidence regarding its oncological efficacy is still debated. We aimed to evaluate oncological outcomes for patients with SRMs who underwent AS in comparison to surgical interventions. METHODS: In April 2024, PubMed, Scopus, and Web of Science were queried for comparative studies evaluating AS in patients with SRMs (PROSPERO: CRD42024530299). The primary outcomes were overall (OS) and cancer-specific survival (CSS). A random-effects model was used for quantitative analysis. KEY FINDINGS AND LIMITATIONS: We identified eight eligible studies (three prospective, four retrospective, and one study based on Surveillance, Epidemiology and End Results [SEER] data) involving 4947 patients. Pooling of data with the SEER data set revealed significantly higher OS rates for patients receiving surgical interventions (hazard ratio [HR] 0.73; p = 0.007), especially partial nephrectomy (PN; HR 0.62; p < 0.001). However, in a sensitivity analysis excluding the SEER data set there was no significant difference in OS between AS and surgical interventions overall (HR 0.84; p = 0.3), but the PN subgroup had longer OS than the AS group (HR 0.6; p = 0.002). Only the study based on the SEER data set showed a significant difference in CSS. The main limitations include selection bias in retrospective studies, and classification of interventions in the SEER database study. CONCLUSIONS AND CLINICAL IMPLICATIONS: Patients treated with AS had similar OS to those who underwent surgery or ablation, although caution is needed in interpreting the data owing to the potential for selection bias and variability in AS protocols. Our review reinforces the need for personalized shared decision-making to identify patients with SRMs who are most likely to benefit from AS. PATIENT SUMMARY: For well-selected patients with a small kidney mass suspicious for cancer, active surveillance seems to be a safe alternative to surgery, with similar overall survival. However, the evidence is still limited and more studies are needed to help in identifying the best candidates for active surveillance.

• MeSH
• Ablation Techniques methods   MeSH
• Humans MeSH
• Kidney Neoplasms * surgery   mortality   pathology   MeSH
• Nephrectomy * methods   MeSH
• Watchful Waiting * MeSH
• Tumor Burden MeSH
• Treatment Outcome MeSH
• Check Tag
• Humans MeSH
• Publication type
• Journal Article MeSH
• Review MeSH
• Comparative Study MeSH
• Systematic Review MeSH

BACKGROUND AND OBJECTIVES: Oligodendrogliomas are primary brain tumors classified as isocitrate deshydrogenase-mutant and 1p19q codeleted in the 2021 World Health Organization Classification of central nervous system tumors. Surgical resection, radiotherapy, and chemotherapy are well-established management options for these tumors. Few studies have evaluated the efficacy of stereotactic radiosurgery (SRS) for oligodendroglioma. As these tumors are less infiltrative than astrocytomas and typically recur locally, focal therapy such as SRS is an appealing option. METHODS: This study was performed through the International Radiosurgery Research Foundation. The objective was to collect retrospective multicenter data on tumor control, clinical response, and morbidity after SRS for oligodendroglioma. Inclusion criteria were age of 18 years or more, single-fraction SRS, and histological confirmation of grade 2 or 3 oligodendroglioma. The primary end points were progression-free survival (PFS) and overall survival from SRS. Secondary end points included clinical evolution and occurrence of adverse radiation events or other complications. Descriptive statistics, Kaplan-Meier analyses, and univariate and multivariate analyses were performed. RESULTS: Eight institutions submitted data for a total of 55 patients. The median follow-up time was 24 months. The median age at SRS was 46 years, and the median Karnofsky Performance Status was 90%. The median marginal dose used was 15 Gy. The median PFS was 17 months, with actuarial rates of 60% at 1 year, 31% at 2 years, and 24% at 5 years after SRS. Factors significantly associated with worsened PFS were World Health Organization grade 3, previous radiotherapy and chemotherapy, and higher marginal dose. The median overall survival post-SRS was 58 months, with actuarial rates of 92% at 1 year, 83% at 2 years, and 49% at 5 years. Karnofsky Performance Status remained stable post-SRS in 51% and worsened in 47% of patients, most often because of tumor progression (73%). Radiation-induced changes occurred in 30% of patients, of which only 4 were symptomatic. CONCLUSION: SRS is a reasonable management option for patients with oligodendroglioma.

• MeSH
• Progression-Free Survival MeSH
• Adult MeSH
• Middle Aged MeSH
• Humans MeSH
• Young Adult MeSH
• Brain Neoplasms * surgery   MeSH
• Oligodendroglioma * surgery   pathology   MeSH
• Radiosurgery * methods   MeSH
• Retrospective Studies MeSH
• Aged MeSH
• Neoplasm Grading MeSH
• World Health Organization * MeSH
• Treatment Outcome MeSH
• Check Tag
• Adult MeSH
• Middle Aged MeSH
• Humans MeSH
• Young Adult MeSH
• Male MeSH
• Aged MeSH
• Female MeSH
• Publication type
• Journal Article MeSH
• Multicenter Study MeSH

Úvod: Burzy jsou tíhové váčky vystlané synoviální vrstvou buněk a obsahují tekutinu podobnou kloubní synovii. Jejich účelem je snižovat mechanické namáhaní (tření) v místech kontaktu šlach s kostí, kloubním pouzdrem anebo vazem. Vlivem různých příčin se může burza zanítit a způsobovat pacientovi obtíže. Burzitidu je možné diagnostikovat zavedením metodiky časného SPECT/CT při vyšetření skeletu. Kazuistiky: Uvádím zde tři pacienty, dva přišli s bolestí kolenních kloubů trvající několik měsíců a jeden s bolestí v oblasti bederní páteře, u kterých byla diagnostikovaná burzitis na třífázové scintigrafii skeletu. Závěr: Dle BOSS klasifikace patří všechny burzitidy do tvz. skupiny C (neboli extraoseální). Tyto patologie na scintigrafii skeletu odhalí pouze provedení SPECT/CT ve fázi blood poolu.

Introduction: Bursae are weight-bearing sacs lined with a synovial layer of cells and contain a fluid similar to joint synovium. Their purpose is to reduce mechanical stress (friction) in the points of contact of tendons with bone, joint capsule or ligament. Due to various reasons, the bursa can become inflamed and cause difficulties for the patient. It is possible to diagnose bursitis by introducing early SPECT/CT methodology during the examination of the skeleton. Case reports: Three patients are presented here, two with pain in the knee joints lasting several months and one with pain in the area of the lumbar spine, who were diagnosed with bursitis on three-phase skeletal scintigraphy. Conclusion: According to the BOSS classification, all bursitis belongs to what is known as group C (or extraosseous). These pathologies on bone scintigraphy can only be detected by performing SPECT/CT in the blood pool phase.

• Keywords
• SPECT/CT krevního poolu,
• MeSH
• Back Pain diagnostic imaging   pathology   MeSH
• Bursitis * diagnostic imaging   MeSH
• Knee Joint diagnostic imaging   pathology   MeSH
• Middle Aged MeSH
• Humans MeSH
• Radionuclide Imaging MeSH
• Single Photon Emission Computed Tomography Computed Tomography * MeSH
• Check Tag
• Middle Aged MeSH
• Humans MeSH
• Male MeSH
• Publication type
• Case Reports MeSH

Cíl: V retrospektivní studii jsme porovnali efektivitu navigace punkce portální žíly pomocí abdominální ultrasonografie oproti CO2 portografii. Efektivitu navigace jsme posuzovali dle počtu punkcí nutných k dosažení katetrizace větve vena portae, délkou skiaskopie a radiační dávkou charakterizovanou produktem dávkové plochy (DAP). Metodika: Do studie bylo zahrnuto 102 po sobě jdoucích pacientů, kterým byl proveden TIPS v období 3 let (od počátku roku 2022 do konce roku 2024). V souboru bylo 29 žen (28 %) a 73 mužů (72 %), ve věkovém rozmezí 27–81 let. Hlavní indikací k TIPS byl refrakterní ascites u 52 (51 %) a krvácení při portální hypertenzi u 50 pacientů (49 %). TIPS byl proveden jako urgentní výkon u 19 pacientů (v 18,6 %) pro nezastavené variceální krvácení. Childovo-Pughovo skóre A bylo 22 % pacientů, Childovo-Pughovo skóre B 44 % a Childovo-Pughovo skóre C 26 %, u 8 % pacientů nebyla klasifikace zjistitelná. Výsledky: Ze 102 TIPS výkonů nebyl tento zaveden u tří pacientů pro technické selhání (2,9 %). Počet vpichů nutných k dosažení portální žíly se zavedením vodiče byl v průměru 5,6 (od jednoho do 20) u 50 pacientů, jejichž punkce byla naváděna pomocí CO2 portografie. U 28 výkonů, kde byl k navádění použit UZ, bylo průměrně nutných 2,7 vpichů (od jednoho do šesti). Délka skiaskopie byla u 28 výkonů provedených pomocí navigace CO2 v průměru 28 minut (9–50 min), u 28 výkonů s navigací pod UZ to bylo 22,8 min (8–43 min). Ve skupině 19 výkonů před obměnou angiolinky a s CO2 navigací byl v průměru DAP 181 497 mGy/cm2 (27 649–399 657 mGy/cm2 ), ve skupině 17 výkonů po obměně angiolinky a navigovaných pomocí CO2 portografie byl DAP v průměru 159 339 mGy/cm2 (52 613–309 440 mGy/cm2 ) a v časově nejmladší skupině 21 výkonů navigovaných pomocí UZ byl DAP v průměru 120 731 mGy/cm 2 (38 180–315 121 mGy/cm2 ). U sedmi výkonů bylo provedeno měření dávky osobními dozimetry. V části výkonu do zavedení vodiče do portální žíly operatér měl dávku v průměru 6 μSv (0 do 12 μSv), zatímco lékař provádějící UZ navigaci v průměru 4,4 μSv (0 do 9 μSv). Celková dávka pro operatéra byla v průměru 19,5 μSv (8–35 μSv). Závěr: Z naměřených hodnot lze uzavřít, že počet vpichů při navigaci pomocí UZ klesl v průměru z 5,6 na 2,7, tento rozdíl se velmi blíží statistické významnosti (p = 0,052). Skiaskopický čas při výkonu klesl v průměru o 7 minut. Dávka druhého lékaře navigujícího punkci pomocí UZ je do doby katetrizace por- tální žíly srovnatelná s dávkou operatéra. DAP klesl po inovaci přístroje a na novém přístroji a dále ještě více klesl i u výkonů prováděných s navigací punkce pomocí UZ.

Aim: In our retrospective study, we compared the efficacy of portal vein puncture navigation using abdominal ultrasonography versus CO2 portography. We assessed navigation efficiency according to the number of punctures required to achieve vena portae branch catheterization, the length of the fluoroscopy, and the dose area product (DAP). Method: The study included 102 consecutive patients who underwent TIPS over a 3-year period (from the beginning of 2022 to the end of 2024). In this cohort, there were 29 women (28%) and 73 men (72%), ranging in age from 27 to 81 years. The main indications for TIPS were refractory ascites in 52 patients (51%) and bleeding with portal hypertension in 50 patients (49%). TIPS was performed as an emergency procedure in 19 patients (18.6%) for uncontrolled variceal bleeding. Child Pugh A, Child Pugh B and Child Pugh C were 22%, 44% and 26% respectively, with 8% of patients having no detectable classification. Results: Of the 102 TIPS procedures, TIPS was not inserted in 3 patients due to technical failure (2.9%). The number of punctures required to reach the portal vein with guidewire insertion averaged 5.6 (range 1 to 20) in 50 patients whose puncture was guided by CO2 portography. In the 28 procedures where ultrasound was used for guidance, the mean number of punctures required was 2.7 (range, 1 to 6). The mean duration of fluoroscopy was 28 min (9–50 min) in the 28 procedures performed with CO2 guidance and 22.8 min (8–43 min) in the 28 procedures with ultrasound guidance. In the group of 19 procedures before angiomachine exchange and with CO2 navigation, the mean DAP was 181 497 mGy/ cm2 (27 649–399 657 mGy/cm2 ), in the group of 17 procedures after angiomachine exchange and navigated by CO 2 portography, the DAP averaged 159 339 mGy/cm 2 (52 613–309 440 mGy/cm2 ) and in the youngest group of 21 procedures navigated by ultrasound, the DAP averaged 120 731 mGy/cm2 (38 180–315 121 mGy/cm 2 ). Dose measurements with personal dosimeters were performed for 7 procedures. In the part of the procedure until the insertion of the guidewire into the portal vein, the operator had a dose of 6 μSv (0 to 12 μSv) on average, while the physician performing the ultrasound navigation had a dose of 4.4 μSv (0 to 9 μSv) on average. The total dose to the operator averaged 19.5 μSv (8 to 35 μSv). Conclusion: From the measured values it can be concluded that the number of punctures during navigation with US decreased from 5.6 to 2.7 on average, this result is close to statistic significance (p = 0.052). The fluoroscopic time during the procedure decreased by 7 minutes. However, the dose of the second physician navigating the puncture using ultrasound is comparable to that of the main operator. The DAP decreased after the device upgrade, and even more decreased for procedures performed with ultrasound-guided puncture navigation.

Introduction: Shame is defined as a negative emotion associated with intense distress and self-blame. It strongly manifests in conditions such as urinary or fecal incontinence. This study aimed to explore the feeling of shame experienced by individuals with incontinence when discussing their condition with others. Additionally, the study sought to identify factors associated with this emotion. Methods: A prospective observational study was conducted with 220 patients with incontinence who filled in a 17-item online survey. Multivariate linear regression analysis was used to identify factors related to shame. Results: A significant sense of shame was reported by 39.1% of participants when discussing their incontinence. The highest levels of shame were observed among women with poorer health status who initially sought advice from general practitioners, had limited knowledge of incontinence, and relied primarily on the internet for information. Conclusion: This study highlights the importance of adopting a comprehensive approach that includes incontinence's emotional and psychological aspects. Educational and awareness interventions are crucial to enhance understanding, provide reliable information, and reduce social stigma. Creating a trusting environment is essential to enable individuals with incontinence to feel comfortable discussing their condition with healthcare professionals, promoting open and supportive communication.

• MeSH
• Adult MeSH
• Fecal Incontinence * psychology   MeSH
• Shame MeSH
• Urinary Incontinence * psychology   MeSH
• Humans MeSH
• Prospective Studies MeSH
• Regression Analysis MeSH
• Aged MeSH
• Statistics as Topic MeSH
• Self Report MeSH
• Check Tag
• Adult MeSH
• Humans MeSH
• Male MeSH
• Aged MeSH
• Female MeSH
• Publication type
• Observational Study MeSH

BACKGROUND AND OBJECTIVES: N-acetyl-l-leucine (NALL) has been established to improve the neurologic manifestations of Niemann-Pick disease type C (NPC) after 12 weeks in a placebo-controlled trial. In the open-label extension phase (EP) follow-up, data were obtained after 12 and 18 months to evaluate the long-term effects of NALL for NPC. METHODS: This is an ongoing, multinational, multicenter EP. Patients with a genetic diagnosis of NPC aged 4 years or older who completed the placebo-controlled trial were eligible to continue in the EP and receive orally administered NALL 2-3 times per day in 3 tiers of weight-based dosing. The primary end point is the modified 5-domain NPC Clinical Severity Scale (NPC-CSS) (range 0-25 points; lower score representing better neurologic status); data from the EP cohort are compared with the expected annual trajectory of decline (i.e., disease progression) established in natural history studies. Analyses are also performed on exploratory end points, including the 15-domain and 4-domain NPC-CSSs and the Scale for Assessment and Rating of Ataxia (SARA). RESULTS: Fifty-three patients aged 5-67 years (45.3% female, 54.7% male) were enrolled in the EP. After 12 months, the mean (±SD) change from baseline on the 5-domain NPC-CSS was -0.27 (±2.42) with NALL vs +1.5 (±3.16) in the historical cohort (95% CI -3.05 to -0.48; p = 0.009), corresponding to a 118% reduction in annual disease progression. After 18 months, the mean (±SD) change was +0.05 (±2.95) with NALL vs +2.25 (±4.74) in the historical cohort (95% CI -4.06 to -0.35; p = 0.023). The 15-domain and 4-domain NPC-CSSs were consistent with the 5-domain NPC-CSS. The improvements in neurologic manifestations demonstrated in the placebo-controlled trial on the primary SARA end point were sustained over the long-term follow-up. NALL was well tolerated, and no treatment-related adverse events or serious reactions occurred. DISCUSSION: Treatment with NALL was associated with a significant reduction in NPC disease progression after 12 and 18 months, demonstrating a disease-modifying, neuroprotective effect. TRIAL REGISTRATION INFORMATION: The trial is registered with ClinicalTrials.gov (NCT05163288; registered December 6, 2021), EudraCT (2021-005356-10). The first patient was enrolled into the EP on March 8, 2023. The trial was funded by IntraBio Inc. CLASSIFICATION OF EVIDENCE: This study provides Class IV evidence that NALL reduces disease progression in NPC.

• MeSH
• Child MeSH
• Adult MeSH
• Double-Blind Method MeSH
• Leucine * analogs & derivatives   therapeutic use   MeSH
• Middle Aged MeSH
• Humans MeSH
• Adolescent MeSH
• Young Adult MeSH
• Follow-Up Studies MeSH
• Neuroprotective Agents * therapeutic use   MeSH
• Niemann-Pick Disease, Type C * drug therapy   MeSH
• Child, Preschool MeSH
• Disease Progression MeSH
• Severity of Illness Index MeSH
• Treatment Outcome MeSH
• Check Tag
• Child MeSH
• Adult MeSH
• Middle Aged MeSH
• Humans MeSH
• Adolescent MeSH
• Young Adult MeSH
• Male MeSH
• Child, Preschool MeSH
• Female MeSH
• Publication type
• Journal Article MeSH
• Multicenter Study MeSH
• Randomized Controlled Trial MeSH

U pacientů s časným karcinomem hrtanu je v současnosti chirurgická léčba zachovávající funkci hrtanu preferovanou primární léčebnou modalitou. Cílem je odstranění karcinomu hrtanu s negativními okraji se současným zachováním přiměřené kvality hlasu a dýchání bez nutnosti tracheostomie. Mezi chirurgické postupy šetřící hrtan patří transorální endoskopická chirurgie, robotická mikrochirurgie hrtanu a vertikální parciální laryngektomie ze zevního přístupu (VPL). Cíl: Cílem studie bylo analyzovat faktory, které jsou zohledňovány při současných indikacích parciálních laryngektomií prováděných ze zevního přístupu pro glotický karcinom a zhodnotit chirurgické a onkologické výsledky těchto operací. Materiál a metodika: Do retrospektivní studie bylo zařazeno 18 pacientů, u nichž byla od 1. 1. 2012 do 31. 12. 2022 na Klinice otorinolaryngologie a chirurgie hlavy a krku FN u sv. Anny v Brně provedena VPL pro glotický spinocelulární karcinom. U 12 (67 %) pacientů byla předléčebná klasifikace nádoru cT1, u 6 (33 %) pacientů cT2. Nejčastěji prováděným výkonem byla laryngofi sura s rozšířenou chordektomií, která byla indikována u 17 (94 %) pacientů; frontální parciální laryngektomie byla provedena u jednoho pacienta (6 %). Nejčastější indikací k VPL byla konverze původně zvoleného endoskopického přístupu u 10 (56 %) pacientů, u 3 (17 %) pacientů se jednalo o revizní výkon po neradikálním endoskopické operaci a v 5 (28 %) případech byla VPL indikována z jiných důvodů. Výsledky: Mezi nejvýznamnější klinické rizikové faktory zohledněné při indikaci VPL patřily: omezená expozice nitra hrtanu v 11 případech, infiltrace přední komisury v 10 případech, šíření nádoru do paraglotického prostoru v 5 případech, subglotická propagace ve 4 případech, postižení processus vocalis ve 3 případech a nádorové šíření do laryngeálního ventrikulu ve 3 případech. Hodnocení resekčních okrajů prokázalo negativní resekční okraje (R0) u 8 (44 %) pacientů, blízké okraje (R0) u 6 (33 %) pacientů a pozitivní resekční okraje (R1) u 4 (22 %) pacientů. Pooperační průběh byl u většiny pacientů příznivý, přičemž u 15 (71 %) pacientů nenastaly žádné komplikace. Mírné lokální komplikace se vyskytly u 5 (24 %) pacientů, zatímco závažné komplikace nebyly zaznamenány u žádného z nich. Medián doby sledování činil 3,0 roku s interkvartilovým rozptylem 2,0 až 5,0 let. U jednoho pacienta byla dia- gnostikována recidiva karcinomu po VPL a adjuvantní radioterapii. U tohoto pacienta byla finálně indikována záchranná totální laryngektomie. Pravděpodobnost přežití byla stanovena Kaplan-Meierovou analýzou: 1 rok 90,5 %; 2 roky 85,7 %; 3 roky 85,7 %; 4 roky 77,1 %; 5 let 66,1 %. Závěr: Ačkoli jsou indikace pro zevní přístupy v současnosti velmi omezené, VPL stále představují záložní chirurgickou variantu u pacientů s omezenou expozicí vnitra hrtanu a u glotických nádorů postihujících rizikové anatomické sublokality, především přední komisuru a paraglotický prostor. I s ohledem na naše výsledky lze laryngofisuru s rozšířenou chordektomií považovat za hrtan šetřicí postup, který nabízí funkčně přijatelné a onkologicky srovnatelné výsledky léčby časného glotického karcinomu v porovnání s preferovanými endoskopickými přístupy a radioterapií.

For patients with early-stage laryngeal carcinoma, function-preserving surgical treatment is currently the preferred primary therapeutic modality. The goal is to achieve complete tumor removal with negative margins while preserving adequate voice quality and respiration without the need for a tracheostomy. Larynx-preserving surgical approaches include transoral endoscopic surgery, robotic microlaryngeal surgery, and external vertical partial laryngectomy (VPL). Objective: The aim of this study was to analyze the factors influencing current indications for open partial laryngectomies for glottic carcinoma and to evaluate the surgical and oncological outcomes of these procedures. Materials and methods: 18 patients who underwent VPL for glottic squamous cell carcinoma from 1. 1. 2012 to 31. 12. 2022 at the Department of Otorhinolaryngology and Head and Neck Surgery, St. Anne‘s Hospital in Brno were included in the retrospective study. Pre-treatment tumor classification was cT1 in 12 (67%) patients and cT2 in 6 (33%) patients. The most commonly performed procedure was laryngofissure with extended chordectomy in 17 (94%) patients; frontal partial laryngectomy was performed in one patient (6%). The most frequent indication for VPL was conversion of the initially chosen endoscopic approach in 10 (56%) patients, revision surgery following a non-radical endoscopic procedure in 3 (17%) patients, and other indications in 5 (28%) cases. Results: The most significant clinical risk factors considered in the indication for VPL included: limited exposure of the larynx in 11 cases, anterior commissure infiltration in 10 cases, tumor spread to the paraglottic space in 5 cases, subglottic extension in 4 cases, involvement of the vocal process in 3 cases, and tumor spread to the laryngeal ventricle in 3 cases. Evaluation of resection margins showed negative resection margins (R0) in 8 (44%) patients, close margins (R0) in 6 (33%) patients, and positive resection margins (R1) in 4 (22%) patients. Postoperative course was favorable in most patients, with no complications in 15 (71%) patients. Mild local complications occurred in 5 (24%) patients, while no severe complications were noted in any of them. The median follow-up period was 3.0 years, with an interquartile range of 2.0 to 5.0 years. Recurrence of carcinoma after VPL and adjuvant radiotherapy was diagnosed in one patient, who ultimately underwent salvage total laryngectomy. Survival probability was estimated using the Kaplan-Meier analysis: 1-year survival at 90.5%, 2-year survival at 85.7%, 3-year survival at 85.7%, 4-year survival at 77.1%, and 5-year survival at 66.1%. Conclusion: Although indications for external approaches are currently very limited, VPL still represents a salvage surgical option for patients with limited laryngeal exposure and for glottic tumors affecting high-risk anatomical subsites, particularly the anterior commissure and paraglottic space. Even considering our results, laryngofissure with extended cordectomy can be regarded as a larynx-preserving procedure that offers functionally acceptable and oncologically comparable treatment outcomes for early glottic carcinoma in comparison with preferred endoscopic approaches and radiotherapy.

• MeSH
• Laryngectomy * classification   methods   statistics & numerical data   MeSH
• Larynx surgery   pathology   MeSH
• Humans MeSH
• Laryngeal Neoplasms surgery   diagnosis   MeSH
• Otorhinolaryngologic Surgical Procedures methods   MeSH
• Retrospective Studies MeSH
• Carcinoma, Squamous Cell surgery   diagnosis   MeSH
• Treatment Outcome MeSH
• Check Tag
• Humans MeSH

INTRODUCTION: Retroperitoneal lymph node dissection (RPLND) is crucial in managing metastatic germ cell tumors (GCTs), particularly post-chemotherapy. Given the long-term survival of these patients, perioperative morbidity is a significant concern. However, data on RPLND morbidity using predefined reporting standards are scarce. This study aims to address this gap by utilizing updated European Association of Urology (EAU) guidelines for standardized complication reporting. PATIENTS AND METHODS: A retrospective analysis was conducted on patients who underwent RPLND for GCTs between 2010 and 2022. 30-day complications were extracted from digital charts using a predefined procedure-specific catalog. Complications were graded using the Clavien-Dindo classification (CDC), and the Comprehensive Complication Index (CCI) was calculated for each patient. RESULTS: Sixty-nine men underwent RPLND at a median age of 32 years (IQR 25-38). Chemotherapy was administered to 64 patients (93 %), with 48 (70 %) having negative tumor markers. Median tumor diameter was 52 mm (IQR 35-83), and median operative time was 197 min (IQR 128-262). Unilateral template removal was performed in 55 patients (80 %). A total of 157 complications were reported in 66 patients (96 %), with anemia (33 %) and gastrointestinal issues (24 %) being the most common. Five patients (7.2 %) had "major" complications (CDC grade ≥ IIIa), and the median CCI was 12 (IQR 9-23). Using the CCI, the proportion of patients with a "major" complication burden increased to 14 %, compared to 8.5 % by CDC alone. The primary limitation of this study is its retrospective design and the limited 30-day follow-up period. CONCLUSION: Most patients experience postoperative complications after RPLND, though severe complications are rare. These findings could improve patient counseling when discussing testicular cancer therapy options.

• MeSH
• Adult MeSH
• Neoplasms, Germ Cell and Embryonal * surgery   pathology   MeSH
• Humans MeSH
• Lymph Node Excision * adverse effects   MeSH
• Morbidity MeSH
• Follow-Up Studies MeSH
• Postoperative Complications * epidemiology   etiology   MeSH
• Prognosis MeSH
• Retroperitoneal Space surgery   pathology   MeSH
• Retrospective Studies MeSH
• Practice Guidelines as Topic * standards   MeSH
• Testicular Neoplasms * surgery   pathology   MeSH
• Urology standards   MeSH
• Check Tag
• Adult MeSH
• Humans MeSH
• Male MeSH
• Publication type
• Journal Article MeSH
• Scoping Review MeSH